Molecular imaging insights into neurodegeneration: Focus on α-synuclein radiotracers

Journal of Nuclear Medicine

Volumn 55, Issue 9, 2014, Pages 1397-1400

  Shah, Maliha ^a   Seibyl, John ^b   Cartier, Anna ^c   Bhatt, Ram ^c   Catafau, Ana M ^a  

^a SC Trade Center 1   (Spain)

^b INSTITUTE FOR NEURODEGENERATIVE DISORDERS   (United States)

^c ICB International Inc ^*  (United States)

Author keywords

Imaging; Neurodegeneration; Parkinson's; Radiotracer; synuclein

Indexed keywords

ALPHA SYNUCLEIN; BF 227 F 18; PITTSBURGH COMPOUND B; RADIOPHARMACEUTICAL AGENT; SIL 23 I 125; TRACER; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; BINDING SITE; DIFFERENTIAL DIAGNOSIS; DIFFUSE LEWY BODY DISEASE; DISEASE ACTIVITY; DISEASE COURSE; DISEASE MARKER; DOPAMINERGIC SYSTEM; DRUG DISTRIBUTION; DRUG PENETRATION; DRUG PROTEIN BINDING; HUMAN; IMMUNOREACTIVITY; MOLECULAR IMAGING; MOLECULAR RECOGNITION; MOTOR DYSFUNCTION; NERVE DEGENERATION; NIGRONEOSTRIATAL SYSTEM; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PROTEIN AGGREGATION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN TARGETING; SHY DRAGER SYNDROME; SIGNAL NOISE RATIO; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; ANIMAL; DEGENERATIVE DISEASE; IMAGING; METHODOLOGY; PARKINSON'S; REVIEW; Α-SYNUCLEIN;

IMAGING; NEURODEGENERATION; PARKINSON'S; RADIOTRACER; Α-SYNUCLEIN;

ALPHA-SYNUCLEIN; ANIMALS; HUMANS; MOLECULAR IMAGING; NEURODEGENERATIVE DISEASES; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY;

EID: 84907016741     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.113.136515     Document Type: Article

References (25)

1. Burré J, Sharma M, Tsetsenis T, Buchman V, Etherton MR, Sudhof TC. Alphasynuclein promotes SNARE-complex assembly in vivo and in vitro. Science. 2010;329:1663-1667.
2. Seibyl J, Russell D, Jennings D, Marek K. Neuroimaging over the course of Parkinson's disease: from early detection of the at-risk patient to improving pharmacotherapy of later-stage disease. Semin Nucl Med. 2012;42:406-414.
3. Seibyl J, Russell D, Jennings D, Marek K. The molecular basis of dopaminergic brain imaging in Parkinson's disease. Q J Nucl Med Mol Imaging. 2012;56: 4-16.
4. Berg D, Marek K, Ross GW, Poewe W. Defining at-risk populations for Parkinson's disease: lessons from ongoing studies. Mov Disord. 2012;27: 656-665.
5. Iranzo A, Lomena F, Stockner H, et al. Decreased striatal dopamine transporter uptake and substantia nigra hyperechogenicity as risk markers of synucleinopathy in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study. Lancet Neurol. 2010;9:1070-1077.
6. Marek K, Jennings D. Can we image premotor Parkinson disease? Neurology. 2009;72(suppl):S21-S26.
7. Hawkes CH, Del Tredici K, Braak H. A timeline for Parkinson's disease. Parkinsonism Relat Disord. 2010;16:79-84.
8. Dickson DW, Braak H, Duda JE, et al. Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria. Lancet Neurol. 2009;8: 1150-1157.
9. Braak H, Del Tredici K. Neuroanatomy and pathology of sporadic Parkinson's disease. Adv Anat Embryol Cell Biol. 2009;201:1-119.
10. Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med. 2004;351:2498-2508.
11. Brooks DJ, Frey KA, Marek KL, et al. Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease. Exp Neurol. 2003;184 (suppl 1):S68-S79.
12. Paleologou KE, Kragh CL, Mann DM, et al. Detection of elevated levels of soluble alpha-synuclein oligomers in post-mortem brain extracts from patients with dementia with Lewy bodies. Brain. 2009;132:1093-1101.
13. Choi JH, Stubblefield B, Cookson MR, et al. Aggregation of alpha-synuclein in brain samples from subjects with glucocerebrosidase mutations. Mol Genet Metab. 2011;104:185-188.
14. Stefanis L. a-Synuclein in Parkinson's disease. Cold Spring Harb Perspect Med. 2012;2:a009399.
15. Kotzbauer PT, Cairns NJ, Campbell MC, et al. Pathologic accumulation of alphasynuclein and Ab in Parkinson disease patients with dementia. Arch Neurol. 2012;69:1326-1331.
16. Schildknecht S, Gerding HR, Karreman C, et al. Oxidative and nitrative alphasynuclein modifications and proteostatic stress: implications for disease mechanisms and interventions in synucleinopathies. J Neurochem. 2013;125:491-511.
17. Uchihara T, Nakamura A, Mochizuki Y, et al. Silver stainings distinguish Lewy bodies and glial cytoplasmic inclusions: comparison between Gallyas-Braak and Campbell-Switzer methods. Acta Neuropathol. 2005;110:255-260.
18. Anderson JP, Walker DE, Goldstein JM, et al. Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J Biol Chem. 2006;281:29739-29752.
19. Maetzler W, Reimold M, Liepelt I, et al. [11C]PIB binding in Parkinson's disease dementia. Neuroimage. 2008;39:1027-1033.
20. Fodero-Tavoletti MT, Mulligan RS, Okamura N, et al. In vitro characterization of BF227 binding to alpha-synuclein/Lewy bodies. Eur J Pharmacol. 2009;617: 54-58.
21. Kikuchi A, Takeda A, Okamura N, et al. In vivo visualization of alpha-synuclein deposition by carbon-11-labelled 2-[2-(2-dimethylaminothiazol-5-yl)ethenyl]-6- [2-(fluoro)ethoxy]benzoxazole positron emission tomography in multiple system atrophy. Brain. 2010;133:1772-1778.
22. Tomita N, Furukawa K, Okamura N, et al. Brain accumulation of amyloid beta protein visualized by positron emission tomography and BF-227 in Alzheimer's disease patients with or without diabetes mellitus. Geriatr Gerontol Int. 2013;13:215-221.
23. Bagchi DP, Yu L, Perlmutter JS, et al. Binding of the radioligand SIL23 to alphasynuclein fibrils in Parkinson disease brain tissue establishes feasibility and screening approaches for developing a Parkinson disease imaging agent. PLoS ONE. 2013;8:e55031.
24. Fodero-Tavoletti MT, Smith DP, McLean CA, et al. In vitro characterization of Pittsburgh compound-B binding to Lewy bodies. J Neurosci. 2007;27:10365-10371.
25. Ye L, Velasco A, Fraser G, et al. In vitro high affinity alpha-synuclein binding sites for the amyloid imaging agent PIB are not matched by binding to Lewy bodies in postmortem human brain. J Neurochem. 2008;105:1428-1437.